Hemogenyx Pharmaceuticals (LSE:HEMO) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals 3-Year Dividend Growth Rate?

Hemogenyx Pharmaceuticals's Dividends per Share for the six months ended in Dec. 2023 was £0.00.

The historical rank and industry rank for Hemogenyx Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

LSE:HEMO's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Hemogenyx Pharmaceuticals's Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00. As of today, Hemogenyx Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Hemogenyx Pharmaceuticals's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's 3-Year Dividend Growth Rate falls into.

Hemogenyx Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Hemogenyx Pharmaceuticals (LSE:HEMO) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Hemogenyx Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.002
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemogenyx Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>

Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

5HU:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines